Oncobiologics (NASDAQ:OTLK) & Synlogic (NASDAQ:SYBX) Head-To-Head Review

Synlogic (NASDAQ:SYBX) and Oncobiologics (NASDAQ:OTLK) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, valuation, profitability and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations for Synlogic and Oncobiologics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synlogic	1	0	0	0	1.00
Oncobiologics	1	2	2	0	2.20

Oncobiologics has a consensus target price of $5.20, suggesting a potential upside of 687.88%. Given Oncobiologics’ stronger consensus rating and higher possible upside, analysts plainly believe Oncobiologics is more favorable than Synlogic.

Risk & Volatility

Synlogic has a beta of 0.5, meaning that its stock price is 50% less volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.74, meaning that its stock price is 26% less volatile than the S&P 500.

Insider and Institutional Ownership

63.4% of Synlogic shares are held by institutional investors. Comparatively, 11.2% of Oncobiologics shares are held by institutional investors. 2.6% of Synlogic shares are held by company insiders. Comparatively, 1.8% of Oncobiologics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Synlogic and Oncobiologics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synlogic	$8,000.00	1,867.97	-$23.36 million	($0.06)	-20.33
Oncobiologics	$1.35 million	119.02	-$62.42 million	($0.77)	-0.86

Synlogic has higher earnings, but lower revenue than Oncobiologics. Synlogic is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Synlogic and Oncobiologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Synlogic	N/A	-26.47%	-18.00%
Oncobiologics	N/A	N/A	-254.82%

Summary

Oncobiologics beats Synlogic on 7 of the 13 factors compared between the two stocks.

About Synlogic

Synlogic, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618, an orally administered, non-systemically absorbed drug candidate to treat phenylketonuria; SYNB1934, an orally administered, non-systemically absorbed drug candidate, which is in Phase III clinical trial to treat phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate that is in Phase II clinical trial for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. for the research and pre-clinical development of a synthetic biotic medicine for the treatment of inflammatory bowel disease; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Cambridge, Massachusetts.

About Oncobiologics

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.